Immunotherapy has emerged as a pivotal field in cancer treatment, particularly for lymphomas, which include both Hodgkin and non-Hodgkin variants. Rituximab, a pioneering cancer immunotherapy, remains integral to the treatment regimens for B cell non-Hodgkin lymphomas. Recent advancements have seen the approval of CD19-directed chimeric antigen receptor (CAR) T cell therapies and CD20 x CD3 bispecific antibodies for relapsed and refractory aggressive B cell non-Hodgkin lymphomas. Additionally, immune checkpoint inhibitors and CD30 antibody-drug conjugates have significantly improved treatment outcomes for classical Hodgkin lymphoma. Despite these advancements, the clinical results remain suboptimal, highlighting the need for further enhancement of therapeutic options. Current research is focused on addressing these gaps by exploring novel strategies to bolster both innate and adaptive immune responses against cancer, thereby improving the efficacy of immunotherapy for lymphomas.